As age increases, the likelihood of a patients with hematological malignancies having further complications and comorbidities increases. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Raul Cordoba, MD, PhD, of Fundacion Jimenez Diaz University Hospital, Madrid, Spain, discusses the Geriatric Assessment in Hematology (GAH) scale, which is a tool used to predict mortality and direct the treatment of elderly patients with multiple myeloma, chronic lymphocytic leukemia or high risk myelodysplastic syndromes.
The Geriatric Assessment in Hematology (GAH) scale
